Eagle Pharma (EGRX) Sell Off Overdone - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Eagle Pharmaceuticals (EGRX) PT Lowered to $98 at Piper Jaffray Following CRL
March 18, 2016 12:07 PM EDTPiper Jaffray analyst David Amsellem lowered his price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $98.00 (from $121.00) but maintained an Overweight rating after the company received a complete response letter (CRL) from the FDA related to its NDA for Kangio, its ready-to-use (RTU) form of bivalirudin. The... More
Mizuho Securities Cuts Price Target on Eagle Pharmaceuticals (EGRX) as Kangio is Delayed
March 18, 2016 11:13 AM EDTMizuho Securities maintained a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $71.00 (from $81.00), on Kangio Delay. Eagle received a complete response letter (CRL) on Kangio, a reformulated version of MDCO's Angiomax. According to the letter, FDA wants further... More
Eagle Pharmaceuticals (EGRX) Announces Receipt of FDA Complete Response Letter for KANGIO NDA
March 18, 2016 6:52 AM EDTEagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use (RTU), stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial... More
